Japanese Journal of Clinical Oncology Advance Access published online on June 16, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyl043
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Thoracic Surgery and Respiratory Group, Saiseikai Central Hospital, Tokyo, Japan
* To whom correspondence should be addressed. Objective: To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas. Methods: FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry. Results: The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former (P < 0.001). Patients with CR Conclusions: In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing CR
Received December 18, 2005
Accepted April 3, 2006
Original Article
[F-18]Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas
Ken-ichi Watanabe 1,
Hiroaki Nomori 2 *,
Takashi Ohtsuka 1,
Tsuguo Naruke 1,
Akinori Ebihara 1,
Hideki Orikasa 3,
Kazuto Yamazaki 3,
Kimiichi Uno 4,
Toshiaki Kobayashi 5,
and
Tomoyuki Goya 6
2 Department of Thoracic Surgery, Graduate School of Medicine, Kumamoto University, Kumamoto, Japan
3 Department of Pathology, Saiseikai Central Hospital, Tokyo, Japan
4 Nishidai Clinic, Tokyo, Japan
5 Development in Assistive Diagnostic Technology, National Cancer Center Hospital, Tokyo, Japan
6 Department of Surgery, Kyorin University, Mitaka, Tokyo, Japan
Hiroaki Nomori, E-mail: hnomori{at}kaiju.medic.kumamoto-u.ac.jp
Abstract 
0.55 could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001). 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Ohba, H. Nomori, T. Mori, K. Ikeda, H. Shibata, H. Kobayashi, S. Shiraishi, and K. Katahira Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 439 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Erasmus, E. Rohren, and S. G. Swisher Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging Proceedings of the ATS, April 15, 2009; 6(2): 171 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Taylor, P. W. Smith, W. K. Brix, M. R. Wick, N. Theodosakis, B. R. Swenson, B. D. Kozower, and D. R. Jones Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer Eur. J. Cardiothorac. Surg., April 1, 2009; 35(4): 699 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ohba, H. Nomori, H. Shibata, H. Kobayashi, T. Mori, S. Shiraishi, and R. Nakashima Evaluation of Semiquantitative Assessments of Fluorodeoxyglucose Uptake on Positron Emission Tomography Scans for the Diagnosis of Pulmonary Malignancies 1 to 3 cm in Size. Ann. Thorac. Surg., March 1, 2009; 87(3): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Taylor, P. W. Smith, W. K. Brix, M. R. Wick, N. Theodosakis, B. R. Swenson, B. D. Kozower, C. L. Lau, and D. R. Jones Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]
|
|